Development of orally bioavailable bicyclic pyrazolones as inhibitors of tumor necrosis factor-α production

被引：138

作者：

Clark, MP ^{[1
]}

Laughlin, SK ^{[1
]}

Laufersweiler, MJ ^{[1
]}

Bookland, RG ^{[1
]}

Brugel, TA ^{[1
]}

Golebiowski, A ^{[1
]}

Sabat, MP ^{[1
]}

Townes, JA ^{[1
]}

VanRens, JC ^{[1
]}

Djung, JF ^{[1
]}

Natchus, MG ^{[1
]}

De, B ^{[1
]}

Hsieh, LC ^{[1
]}

Xu, SC ^{[1
]}

Walter, RL ^{[1
]}

Mekel, MJ ^{[1
]}

Heitmeyer, SA ^{[1
]}

Brown, KK ^{[1
]}

Juergens, K ^{[1
]}

Taiwo, YO ^{[1
]}

Janusz, MJ ^{[1
]}

机构：

[1] Procter & Gamble Pharmaceut, Mason, OH 45040 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2004年 / 47卷 / 11期

关键词：

D O I：

10.1021/jm049968m

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

2-Aryl-3-pyrimidinyl based tumor necrosis factor-alpha (TNF-alpha) inhibitors, which contain a novel bicyclic pyrazolope core, are described. Many showed low-nanomolar activity against lipopolysaccharide-induced TNF-alpha production in monocytic cells. Secondary screening data are presented for the pyrimidinyl bicyclic pyrazolones. Several of these analogues showed good oral bioavailability in rat and efficacy in the rat iodoacetate in vivo model.

引用

页码：2724 / 2727

页数：4

共 50 条

[31] Feedback inhibition of macrophage tumor necrosis factor-α production by tristetraprolin
Carballo, E
Lai, WS
Blackshear, PJ
SCIENCE, 1998, 281 (5379) : 1001 - 1005
[32] Over pressure load induce production of tumor necrosis factor-α
Li, SY
Ni, XH
Dang, AM
Liu, GZ
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2004, 37 (01) : 290 - 290
[33] Eicosapentaenoic acid decreases tumor necrosis factor-α production.
Zhao, Y
Chen, LH
FASEB JOURNAL, 1999, 13 (05): : A843 - A843
[34] Inhibition of tumor necrosis factor-α production by urinary trypsin inhibitor
Isobe, H
Okajima, K
Uchiba, M
Perenlei, ME
Harada, N
BIOLOGICAL RESPONSE TO PLANNED AND UNPLANNED INJURIES: CELLULAR, MOLECULAR AND GENETIC ASPECTS, 2003, 1255 : 69 - 74
[35] Effect of lactoferrin on the production of tumor necrosis factor-α and nitric oxide
Choe, YH
Lee, SW
JOURNAL OF CELLULAR BIOCHEMISTRY, 2000, 76 (01) : 30 - 36
[36] An orally active tumor necrosis factor-α inhibitor drug candidate for the management of rheumatoid arthritis
Sharma, S
Ghosh, U
Jadhav, S
Khan, A
More, T
Ranaware, A
Gadkari, T
Nair, V
Ahmad, I
Dalal, R
Damre, A
Deshmukh, G
Gupte, R
Kulkarni-Almeida, A
Panicker, R
Parikh, S
Perumal, S
ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S355 - S355
[37] A Case of Tumor Necrosis Factor-α Inhibitors-induced Pustular Psoriasis
Park, Jae-Jeong
Lee, Seung-Chul
ANNALS OF DERMATOLOGY, 2010, 22 (02) : 212 - 215
[38] Medicinal Chemistry of Tumor Necrosis Factor-α Inhibitors and Related Oxidative Stress
Kumar, Neeraj
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2012, 12 (13) : 1391 - 1391
[39] Cutaneous pseudolymphoma caused by tumor necrosis factor-α inhibitors was not induced by ustekinumab
Imafuku, Shinichi
Tatsukawa, Ryoko
Ito, Kotaro
Nakayama, Juichiro
JOURNAL OF DERMATOLOGY, 2012, 39 (12): : 1070 - 1070
[40] Safety and Tolerability of Tumor Necrosis Factor-α Inhibitors in Psoriasis: A Narrative Review
Semble, Ashley L.
Davis, Scott A.
Feldman, Steven R.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2014, 15 (01) : 37 - 43

← 1 2 3 4 5 →